Median Technologies Stock

Equities

ALMDT

FR0011049824

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris 11:35:26 2024-05-28 am EDT 5-day change 1st Jan Change
3.625 EUR +0.55% Intraday chart for Median Technologies +6.93% -23.68%
Sales 2024 * 23.9M 25.95M Sales 2025 * 44.18M 47.97M Capitalization 66.31M 72.01M
Net income 2024 * -24M -26.06M Net income 2025 * -20M -21.72M EV / Sales 2024 * 3.58 x
Net Debt 2024 * 19.25M 20.9M Net Debt 2025 * 39.23M 42.61M EV / Sales 2025 * 2.39 x
P/E ratio 2024 *
-2.66 x
P/E ratio 2025 *
-3.21 x
Employees 256
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.55%
1 week+6.93%
Current month+39.69%
1 month+31.82%
3 months-6.69%
6 months-9.26%
Current year-23.68%
More quotes
1 week
3.47
Extreme 3.465
3.89
1 month
2.50
Extreme 2.5
3.89
Current year
2.33
Extreme 2.325
5.06
1 year
2.33
Extreme 2.325
6.77
3 years
2.33
Extreme 2.325
18.32
5 years
0.93
Extreme 0.93
18.32
10 years
0.90
Extreme 0.9
18.32
More quotes
Managers TitleAgeSince
Founder 62 01-12-31
Director of Finance/CFO - 21-07-11
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 20-06-24
Chairman 62 08-03-25
Director/Board Member 67 15-11-29
More insiders
Date Price Change Volume
24-05-28 3.625 +0.55% 38 431
24-05-27 3.605 -2.57% 63,253
24-05-24 3.7 -1.20% 48,499
24-05-23 3.745 +7.61% 148,943
24-05-22 3.48 +2.65% 199,391

Real-time Euronext Paris, May 28, 2024 at 11:35 am EDT

More quotes
Median Technologies offers innovative imaging solutions and services to improve healthcare for all. The group uses the power of phenomic imaging to contribute to the emergence of new therapies and treatment strategies for patients. Its solutions, «iSee» for the image management in oncology trials and «eyonisTM» (formerly iBiopsy®), its phenomic imaging platform, combined with the expertise of its teams are an essential part to the discovery of new drugs and diagnostic tools to monitor diseases and evaluate the response of patients to their therapy. Median Technologies is helping biopharmaceutical companies and healthcare professionals quickly and accurately introduce new treatments to patients who need them, with a view to reducing overall costs of care. Provision of services accounts for all net sales. Net sales are distributed geographically as follows: China (41.6%), the United States and Canada (30.4%), Europe and other (28%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.605 EUR
Average target price
24.18 EUR
Spread / Average Target
+570.60%
Consensus

Annual profits - Rate of surprise